Breathe Well Live Well
|
AstraZeneca Buys Synairgen Asthma Drug For $7.25M
BioResearch Online (press release) AstraZeneca announced that it has signed into a global license agreement with Synairgen, a pharmaceutical company focused on respiratory disease, to buy SNG001, a novel immuno-modulatory therapy for viral-induced exacerbation in asthma. SNG001 is … |
View full post on asthma – Google News
|
AstraZeneca enters into $232m asthma drug deal with Synairgen
Pharmaceutical Business Review AstraZeneca has entered into a global licence agreement with Synairgen for SNG001, a new, inhaled interferon beta (IFN-beta) being developed for the treatment of respiratory tract viral infections in patients with severe asthma. AstraZeneca … |
View full post on asthma – Google News
|
AstraZeneca Buys Rights to Synairgen Asthma Compound
Genetic Engineering News SNG001 is an inhaled interferon beta (IFN-beta) for respiratory tract viral infections in patients with severe asthma. AstraZeneca said it plans early next years to launch a Phase IIa study of SNG001 in patients with severe asthma—a trial it said … |
View full post on asthma – Google News
|
UPDATE 1-AstraZeneca builds pipeline with $232 mln Synairgen asthma deal
Reuters LONDON, June 12 (Reuters) – AstraZeneca has struck a deal worth up to $232 million in milestone payments to acquire rights to a drug from Synairgen for treating respiratory tract viral infections in patients with severe asthma. Britain's second-biggest … |
View full post on asthma – Google News
Reuters UK |
AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Fox Business AstraZeneca has struck a deal worth up to $232 million in milestone payments to acquire rights to a drug from Synairgen for treating respiratory tract viral infections in patients with severe asthma. Britain's second-biggest drugmaker – subject of a … AstraZeneca extends global shopping spree with $232M asthma drug deal Synairgen breathes easier with $225M from Astrazeneca for its asthma drug |
View full post on asthma – Google News
Reuters |
AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Reuters AstraZeneca plans to start a mid-stage Phase IIa study with the drug in early 2015 in patients with severe asthma, building on results from an initial Phase lla trial in a broad asthma population. Severe asthma is a growing focus for major drugmakers … Synairgen shares soar on AstraZeneca asthma deal AstraZeneca licenses rights to Synairgen asthma drug |
View full post on asthma – Google News
|
AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Yahoo News LONDON (Reuters) – AstraZeneca has struck a deal worth up to $232 million in milestone payments to acquire rights to a drug from Synairgen for treating respiratory tract viral infections in patients with severe asthma. Britain's second-biggest … AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen AstraZeneca licenses rights to Synairgen asthma drug Synairgen shares soar on AstraZeneca asthma deal |
View full post on asthma – Google News
|
AstraZeneca licenses rights to Synairgen asthma drug
Yahoo News LONDON (Reuters) – AstraZeneca has struck a deal worth up to $232 million in milestone payments to license in rights to a drug from Synairgen for viral-induced exacerbation in asthma. Britain's second biggest drugmaker – subject of a takeover bid by … |
View full post on asthma – Google News
|
Synairgen in Drug Partnership Talks After Study Results
Businessweek Synairgen Plc (SNG) is in talks with potential partners following the results of a study of an experimental medicine targeting infections that trigger asthma attacks, Chief Executive Officer Richard Marsden said. Synairgen is speaking with larger … New drug 'stops common cold asthma deaths' |
View full post on asthma – Google News
|
Synairgen in Drug Partnership Talks After Asthma Study Results
Businessweek Synairgen Plc (SNG) is in talks with potential partners following the results of a study of an experimental drug targeting infections that trigger asthma attacks, Chief Executive Officer Richard Marsden said. Synairgen is speaking with larger … |
View full post on asthma – Google News